From our December 2020 Newsletter
Overcoming Pediatric Drug-Resistant TB Crisis
Special message from Dr. Tereza Kasaeva, Director of WHO's Global TB Program, on the occasion of World Children's Day and World Antimicrobial Awareness Week.
From our November 2020 Newsletter
TAG's 2020 Pipeline Report: TB chapters released
TAG released newly available TB chapters of its 2020 Pipeline Report. This annual publication reviews progress in research and development for TB diagnostic, preventive, and treatment innovations.
‘Urgent investment required’ to get TB efforts back on track, group says
The group found that TB-related targets established in 2018 during a high-level meeting of the United Nations General Assembly are not on track to be met by 2022, and that COVID-19 has rolled back efforts in some cases.
From our October 2020 Newsletter
Landmark TB Trial Identifies Shorter-Course Treatment Regimen
Results from an international, randomized, controlled clinical trial indicate that a four-month daily treatment regimen containing high-dose, or “optimized,” rifapentine with moxifloxacin is as safe and effective as the existing standard six-month daily regimen at curing drug-susceptible tuberculosis (TB) disease.
From our September 2020 Newsletter
The European Medicines Agency has updated its stance on Deltyba—with implications for children with DR-TB.
The driving contributor to safer, all-oral TB regimens may not be who you think, with more credit due to the government than private enterprises.
From our August 2020 Newsletter
Union welcomes EC authorization of TB Alliance’s BPaL treatment for drug-resistant TB
On August 3rd, a new treatment developed by the TB Alliance has been approved by the European Commission for some of the most drug-resistant forms of TB. Learn more about the new Pretomanid drug here.
From our July 2020 Newsletter
COVID-19 Disruptions May Raise Cancer, HIV, TB Cases, Deaths Globally
Mounting evidence suggests the ongoing pandemic will have significant implications for the treatment and pathology of other burdensome diseases—tuberculosis included.
Rapid Drug-Resistant Tuberculosis Diagnostics Test is Launched
The new Xpert MTB/XDR from Cepheid offers huge advancements in the profiling of MDR and XDR-TB—minimizing turnaround time and complexity while increasing accessibility.